CD8A and cancer: Because of significant role of CD8+ T cell in anti-cancer immunotherapy, hence, finding new biomarkers and constructing a CD8+ T cell-related classifier to predict the prognosis and effect of immunotherapy have a significant meaning for patients with stage III LUAD.